Used in the treatment of schizophrenia and other psychotic disorders, Pardoprunox hydrochloride acts as a dopamine D2 and serotonin 5-HT1A receptor partial agonist while also antagonizing 5-HT2A receptors. This dual mechanism helps improve both positive and negative symptoms of schizophrenia with a potentially lower risk of extrapyramidal side effects compared to typical antipsychotics. It has also shown antidepressant and anxiolytic effects in preclinical models, suggesting possible utility in mood disorders. Clinical development focused on its efficacy and tolerability profile in early-phase trials, although it has not reached widespread clinical use.